GLP-1 Weight-Loss Drugs Linked to Higher Osteoporosis and Gout Risk

A new observational study of more than 146,000 adults with obesity and type 2 diabetes finds that GLP-1 medications (e.g., Ozempic, Wegovy, Victoza, Saxenda) are associated with modestly higher risks of osteoporosis (about 30% increase) and gout (about 12%), though causality can’t be established. Potential explanations include rapid weight loss and nutrient deficits, and findings echo some prior research and FDA labeling. Researchers caution that diet, exercise, vitamin D and calcium intake, and other factors weren’t fully captured. More research is needed, but clinicians may consider monitoring bone health and advising lifestyle measures alongside GLP-1 use rather than avoiding therapy altogether.